nach oben

Journal of Neurology

Erschienen in:

07.09.2016 | Review

Vaccines and multiple sclerosis: a systematic review

verfasst von: Mia Topsøe Mailand, Jette Lautrup Frederiksen

Erschienen in: Journal of Neurology | Ausgabe 6/2017

Einloggen, um Zugang zu erhalten

Abstract

Vaccinations are often the most effective tool against some disease known to mankind. This study offers a literature review on the role of vaccines regarding the risk of developing multiple sclerosis (MS) and MS relapse. The method used in this study is a systematic literature review on the database PubMed. The study found no change in risk of developing multiple sclerosis (MS) after vaccination against hepatitis B virus, human papillomavirus, seasonal influenza, measles–mumps–rubella, variola, tetanus, Bacillus Calmette-Guérin (BCG), polio, or diphtheria. No change in risk of relapse was found for influenza. Further research is needed for the potential therapeutic use of the BCG vaccine in patients in risk of developing MS and for the preventive potential of the tetanus and diphtheria vaccine.

Denis F, Levy-Bruhl D (2006) Mass vaccination against hepatitis B: the French example. Curr Top Microbiol Immunol 304:115–129PubMed

Williamson EM, Berger JR (2015) Infection risk in patients on multiple sclerosis therapeutics. CNS Drugs 29(3):229–244CrossRefPubMed

Demicheli V et al (2003) Hepatitis B vaccination and multiple sclerosis: evidence from a systematic review. J Viral Hepat 10(5):343–344CrossRefPubMed

DeStefano F, Verstraeten T, Chen RT (2002) Hepatitis B vaccine and risk of multiple sclerosis. Expert Rev Vaccines 1(4):461–466CrossRefPubMed

Farez MF, Correale J (2011) Immunizations and risk of multiple sclerosis: systematic review and meta-analysis. J Neurol 258(7):1197–1206CrossRefPubMed

Gout O (2001) Vaccinations and multiple sclerosis. Neurol Sci 22(2):151–154CrossRefPubMed

Jefferson T, Heijbel H (2001) Demyelinating disease and hepatitis B vaccination: is there a link? Drug Saf 24(4):249–254CrossRefPubMed

Loebermann M et al (2011) Vaccination against infection in patients with multiple sclerosis. Nat Rev Neurol 8(3):143–151CrossRef

Merelli E, Casoni F (2000) Prognostic factors in multiple sclerosis: role of intercurrent infections and vaccinations against influenza and hepatitis B. Neurol Sci 21(4 Suppl 2):S853–S856CrossRefPubMed

10.

Sievers EJ, Heyneman CA (2002) Relationship between vaccinations and multiple sclerosis. Ann Pharmacother 36(1):160–162CrossRefPubMed

11.

Ascherio A et al (2001) Hepatitis B vaccination and the risk of multiple sclerosis. N Engl J Med 344(5):327–332CrossRefPubMed

12.

DeStefano F et al (2003) Vaccinations and risk of central nervous system demyelinating diseases in adults. Arch Neurol 60(4):504–509CrossRefPubMed

13.

Eftekharian MM et al (2014) Multiple sclerosis and immunological-related risk factors: results from a case-control study. Hum Antibodies 23(1–2):31–36PubMed

14.

Geier DA, Geier MR (2005) A case-control study of serious autoimmune adverse events following hepatitis B immunization. Autoimmunity 38(4):295–301CrossRefPubMed

15.

Hernan MA et al (2004) Recombinant hepatitis B vaccine and the risk of multiple sclerosis: a prospective study. Neurology 63(5):838–842CrossRefPubMed

16.

Hocine MN et al (2007) Hepatitis B vaccination and first central nervous system demyelinating events: reanalysis of a case-control study using the self-controlled case series method. Vaccine 25(31):5938–5943CrossRefPubMed

17.

Langer-Gould A et al (2014) Vaccines and the risk of multiple sclerosis and other central nervous system demyelinating diseases. JAMA Neurol 71(12):1506–1513CrossRefPubMed

18.

Mikaeloff Y et al (2007) Hepatitis B vaccine and risk of relapse after a first childhood episode of CNS inflammatory demyelination. Brain 130(Pt 4):1105–1110PubMed

19.

Mikaeloff Y et al (2007) Hepatitis B vaccination and the risk of childhood-onset multiple sclerosis. Arch Pediatr Adolesc Med 161(12):1176–1182CrossRefPubMed

20.

Mikaeloff Y et al (2009) Hepatitis B vaccine and the risk of CNS inflammatory demyelination in childhood. Neurology 72(10):873–880CrossRefPubMed

21.

Ozakbas S et al (2006) Development of multiple sclerosis after vaccination against hepatitis B: a study based on human leucocyte antigen haplotypes. Tissue Antigens 68(3):235–238CrossRefPubMed

22.

Ramagopalan SV et al (2009) Association of infectious mononucleosis with multiple sclerosis. A population-based study. Neuroepidemiology 32(4):257–262CrossRefPubMed

23.

Sadovnick AD, Scheifele DW (2000) School-based hepatitis B vaccination programme and adolescent multiple sclerosis. Lancet 355(9203):549–550CrossRefPubMed

24.

Touze E et al (2002) Hepatitis B vaccination and first central nervous system demyelinating event: a case-control study. Neuroepidemiology 21(4):180–186CrossRefPubMed

25.

Zipp F, Weil JG, Einhaupl KM (1999) No increase in demyelinating diseases after hepatitis B vaccination. Nat Med 5(9):964–965CrossRefPubMed

26.

Confavreux C et al (2001) Vaccinations and the risk of relapse in multiple sclerosis. Vaccines in Multiple Sclerosis Study Group. N Engl J Med 344(5):319–326CrossRefPubMed

27.

Chao C et al (2012) Surveillance of autoimmune conditions following routine use of quadrivalent human papillomavirus vaccine. J Intern Med 271(2):193–203CrossRefPubMed

28.

Grimaldi-Bensouda L et al (2014) Autoimmune disorders and quadrivalent human papillomavirus vaccination of young female subjects. J Intern Med 275(4):398–408CrossRefPubMed

29.

Pellegrino P et al (2013) No evidence of a link between multiple sclerosis and the vaccine against the human papillomavirus. Eur J Epidemiol 28(8):705–707CrossRefPubMed

30.

Scheller NM et al (2015) Quadrivalent HPV vaccination and risk of multiple sclerosis and other demyelinating diseases of the central nervous system. JAMA 313(1):54–61CrossRefPubMed

31.

Alter M, Speer J (1968) Clinical evaluation of possible etiologic factors in multiple sclerosis. Neurology 18(2):109–116CrossRefPubMed

32.

Bardage C et al (2011) Neurological and autoimmune disorders after vaccination against pandemic influenza A (H1N1) with a monovalent adjuvanted vaccine: population based cohort study in Stockholm, Sweden. Bmj 343:d5956CrossRefPubMedPubMedCentral

33.

Zorzon M et al (2003) Risk factors of multiple sclerosis: a case-control study. Neurol Sci 24(4):242–247CrossRefPubMed

34.

Auriel E et al (2012) Seasonal and H1N1v influenza vaccines in MS: safety and compliance. J Neurol Sci 314(1–2):102–103CrossRefPubMed

35.

Bamford CR, Sibley WA, Laguna JF (1978) Swine influenza vaccination in patients with multiple sclerosis. Arch Neurol 35(4):242–243CrossRefPubMed

36.

De Keyser J, Zwanikken C, Boon M (1998) Effects of influenza vaccination and influenza illness on exacerbations in multiple sclerosis. J Neurol Sci 159(1):51–53CrossRefPubMed

37.

Farez MF et al (2012) H1N1 vaccination does not increase risk of relapse in multiple sclerosis: a self-controlled case-series study. Mult Scler 18(2):254–256CrossRefPubMed

38.

McNicholas N, Chataway J (2011) Relapse risk in patients with multiple sclerosis after H1N1 vaccination, with or without seasonal influenza vaccination. J Neurol 258(8):1545–1547CrossRefPubMed

39.

Michielsens B et al (1990) Serial magnetic resonance imaging studies with paramagnetic contrast medium: assessment of disease activity in patients with multiple sclerosis before and after influenza vaccination. Eur Neurol 30(5):258–259CrossRefPubMed

40.

Miller AE et al (1997) A multicenter, randomized, double-blind, placebo-controlled trial of influenza immunization in multiple sclerosis. Neurology 48(2):312–314CrossRefPubMed

41.

Mokhtarian F et al (1997) Influenza virus vaccination of patients with multiple sclerosis. Mult Scler 3(4):243–247CrossRefPubMed

42.

Moriabadi NF et al (2001) Influenza vaccination in MS: absence of T-cell response against white matter proteins. Neurology 56(7):938–943CrossRefPubMed

43.

Myers LW et al (1977) Swine influenza virus vaccination in patients with multiple sclerosis. J Infect Dis 136(Suppl):S546–S554CrossRefPubMed

44.

Salvetti M et al (1995) Clinical and MRI assessment of disease activity in patients with multiple sclerosis after influenza vaccination. J Neurol 242(3):143–146CrossRefPubMed

45.

Sibley WA, Bamford CR, Laguna JF (1976) Influenza vaccination in patients with multiple sclerosis. JAMA 236(17):1965–1966CrossRefPubMed

46.

Sibley WA, Foley JM (1965) Infection and immunization in multiple sclerosis. Ann N Y Acad Sci 122:457–466CrossRefPubMed

47.

Ahlgren C et al (2009) A population-based case-control study on viral infections and vaccinations and subsequent multiple sclerosis risk. Eur J Epidemiol 24(9):541–552CrossRefPubMed

48.

Bansil S et al (1997) Multiple sclerosis in India: a case-control study of environmental exposures. Acta Neurol Scand 95(2):90–95CrossRefPubMed

49.

Kurtzke JF et al (1997) Multiple sclerosis in the Faroe Islands. 7. Results of a case control questionnaire with multiple controls. Acta Neurol Scand 96(3):149–157CrossRefPubMed

50.

Pekmezovic T, Jarebinski M, Drulovic J (2004) Childhood infections as risk factors for multiple sclerosis: Belgrade case-control study. Neuroepidemiology 23(6):285–288CrossRefPubMed

51.

Zilber N, Kahana E (1996) Risk factors for multiple sclerosis: a case-control study in Israel. Acta Neurol Scand 94(6):395–403CrossRefPubMed

52.

Ahlgren C et al (2009) Multiple sclerosis incidence in the era of measles-mumps-rubella mass vaccinations. Acta Neurol Scand 119(5):313–320CrossRefPubMed

53.

Andersen E, Isager H, Hyllested K (1981) Risk factors in multiple sclerosis: tuberculin reactivity, age at measles infection, tonsillectomy and appendectomy. Acta Neurol Scand 63(2):131–135CrossRefPubMed

54.

Casetta I et al (1994) Environmental risk factors and multiple sclerosis: a community-based, case-control study in the province of Ferrara, Italy. Neuroepidemiology 13(3):120–128CrossRefPubMed

55.

Compston DA et al (1986) Viral infection in patients with multiple sclerosis and HLA-DR matched controls. Brain 109(Pt 2):325–344CrossRefPubMed

56.

Berr C et al (1989) Risk factors in multiple sclerosis: a population-based case-control study in Hautes-Pyrenees, France. Acta Neurol Scand 80(1):46–50CrossRefPubMed

57.

Ristori G et al (1999) Use of Bacille Calmette–Guerin (BCG) in multiple sclerosis. Neurology 53(7):1588–1589CrossRefPubMed

58.

Farez MF, Correale J (2011) Yellow fever vaccination and increased relapse rate in travelers with multiple sclerosis. Arch Neurol 68(10):1267–1271CrossRefPubMed

59.

Baumhackl U et al (2003) A controlled trial of tick-borne encephalitis vaccination in patients with multiple sclerosis. Vaccine 21(Suppl 1):S56–S61CrossRefPubMed

60.

Quast U, Herder C, Zwisler O (1991) Vaccination of patients with encephalomyelitis disseminata. Vaccine 9(4):228–230CrossRefPubMed

61.

Ristori G et al (2014) Effects of Bacille Calmette-Guerin after the first demyelinating event in the CNS. Neurology 82(1):41–48CrossRefPubMedPubMedCentral

62.

Pool V, Gordon DM, Decker M (2012) Methodological issues with the risk of relapse study in patients with multiple sclerosis after yellow fever vaccination. Arch Neurol 69(1):144 (author reply 144-5) CrossRefPubMed

Titel: Vaccines and multiple sclerosis: a systematic review
verfasst von: Mia Topsøe Mailand
Jette Lautrup Frederiksen
Publikationsdatum: 07.09.2016
Verlag: Springer Berlin Heidelberg
Erschienen in: Journal of Neurology / Ausgabe 6/2017
Print ISSN: 0340-5354
Elektronische ISSN: 1432-1459
DOI: https://doi.org/10.1007/s00415-016-8263-4

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Sozialer Aufstieg verringert Demenzgefahr

24.05.2024 Demenz Nachrichten

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Was nützt die Kraniektomie bei schwerer tiefer Hirnblutung?

17.05.2024 Hirnblutung Nachrichten

Eine Studie zum Nutzen der druckentlastenden Kraniektomie nach schwerer tiefer supratentorieller Hirnblutung deutet einen Nutzen der Operation an. Für überlebende Patienten ist das dennoch nur eine bedingt gute Nachricht.

Thrombektomie auch bei großen Infarkten von Vorteil

16.05.2024 Ischämischer Schlaganfall Nachrichten

Auch ein sehr ausgedehnter ischämischer Schlaganfall scheint an sich kein Grund zu sein, von einer mechanischen Thrombektomie abzusehen. Dafür spricht die LASTE-Studie, an der Patienten und Patientinnen mit einem ASPECTS von maximal 5 beteiligt waren.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2017

Plasma exchanges for severe acute neurological deterioration in patients with IgM anti-myelin-associated glycoprotein (anti-MAG) neuropathy

Screening for lipoprotein receptor-related protein 4-, agrin-, and titin-antibodies and exploring the autoimmune spectrum in myasthenia gravis

Clinicopathological features of multiple mononeuropathy associated with systemic lupus erythematosus: a multicenter study

Characteristics associated with quality of life among people with drug-resistant epilepsy

Varicella zoster virus encephalitis in a patient with a solid carcinoma: a case report